NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023
2023 · Journal of the National Comprehensive Cancer Network · 449 citations
https://doi.org/10.6004/jnccn.2023.0020
T
Tejas Patil
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
184
Papers
3.3K
Citations
24
h-index
43
i10-index
Tejas Patil is an academic researcher. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Lung Cancer Diagnosis and Treatment. The author has an h-index of 24, co-authored 157 publications.
ORCID: 0000-0003-4389-1010Papers by this author
worksLong-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
2022 · JTO Clinical and Research Reports · 111 citations
https://doi.org/10.1016/j.jtocrr.2022.100332
Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer
2018 · Cancer · 79 citations
https://doi.org/10.1002/cncr.31871
A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer
2021 · npj Precision Oncology · 40 citations
https://doi.org/10.1038/s41698-021-00181-4
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non–Small-Cell Lung Cancer
2019 · Clinical Lung Cancer · 37 citations
https://doi.org/10.1016/j.cllc.2019.11.008
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations
2024 · Lung Cancer · 10 citations
https://doi.org/10.1016/j.lungcan.2024.108040
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat